EGBN (Eagle Bancorp Inc) Stock Analysis - SEC Filings

Eagle Bancorp Inc (EGBN) is a publicly traded Financial Services sector company. As of May 21, 2026, EGBN trades at $25.72 with a market cap of $765.14M and a P/E ratio of -6.21. EGBN moved +3.12% today. Year to date, EGBN is +19.61%; over the trailing twelve months it is +39.38%. Its 52-week range spans $15.03 to $30.94. Analyst consensus is buy with an average price target of $30.50. Rallies surfaces EGBN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Where can I find EGBN SEC filings?

Rallies organizes EGBN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.

EGBN Key Metrics

Key financial metrics for EGBN
MetricValue
Price$25.72
Market Cap$765.14M
P/E Ratio-6.21
EPS$-4.12
Dividend Yield0.01%
52-Week High$30.94
52-Week Low$15.03
Volume463
Avg Volume0
Revenue (TTM)$582.97M
Net Income$-125.01M
Gross Margin0.00%

Latest EGBN News

Recent EGBN Insider Trades

  • Mathews Louis P. Jr. bought 1.50K (~$25.80K) on Nov 21, 2025.
  • Mathews Louis P. Jr. bought 1.50K (~$25.26K) on Nov 19, 2025.
  • Newell Eric R bought 3.05K (~$50.47K) on Nov 14, 2025.

EGBN Analyst Consensus

2 analysts cover EGBN: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $30.50.

Common questions about EGBN

Where can I find EGBN SEC filings?
Rallies organizes EGBN SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
Does Rallies show EGBN 10-K and 10-Q filings?
Rallies organizes EGBN SEC filing research, including 10-K reports, 10-Q reports, company disclosures, and filing-driven context when available.
Is EGBN research on Rallies investment advice?
No. Rallies provides research, data, and educational context for EGBN. It does not provide personalized investment advice.
EGBN

EGBN